Entera Bio Ltd.

ENTX

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001638097

SEC filings (opens in a new tab)

No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Entera Bio Ltd. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of ENTX: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Q4 2023	Change
Holders	12	10	−2
Shares	2.58M	4.06M	+1.48M (+57.5%)
Value	$1.87M	$2.44M	+$566.8K (+30.3%)

New holders (2)

Institutions that held Entera Bio Ltd. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ENTX in Q4 2023
Institution	Shares	Value	% of portfolio
Two Sigma Securities, LLC	69,441	$41.7K	0.00%
Royal Bank of Canada	200	$0	0.00%

Sold out (4)

Institutions that held Entera Bio Ltd. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of ENTX in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
Citadel Advisors LLC	15,368	$11.1K
UBS Group AG	614	$445
Stonebridge Capital Advisors LLC	200	$145
Simplex Trading, LLC	86	$0